T. Uwagawa

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
T Uwagawa, Tadashi Uwagawa
Publication record
133 papers · 2,148 citations · H-index 24

PAPERS

Impact of thyroid-stimulating hormone ratio change on the progression-free survival of patients receiving gemcitabine, cisplatin, and durvalumab therapy for advanced biliary tract cancer.
20260 citationsauthor #11
The preoperative cachexia index predicts outcomes after pancreatic resection for resectable pancreatic cancer
20252 citationsauthor #12
Prognostic significance of the hemoglobin, albumin, lymphocyte, platelet (HALP) score after hepatectomy for colorectal liver metastases
20255 citationsauthor #11
Significance of Neutrophil-to-Lymphocyte Ratio in Predicting the Efficacy of Anamorelin for Cancer Cachexia
20252 citationsauthor #4
The minimum apparent diffusion coefficient value on preoperative magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biologically borderline resectable pancreatic cancer
20252 citationsauthor #7
A successfully resected case of giant hepatic hemangioma with symptomatic massive pleural effusion: a case report
20250 citationsauthor #8
Multicenter observational study to characterize fibroblast growth factor receptor 2 fusions or rearrangements in patients with advanced/metastatic cholangiocarcinoma
20253 citationsauthor #12
Signal heterogeneity in apparent diffusion coefficient map of magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biological borderline resectable pancreatic cancer.
20250 citationsauthor #7
Pulmonary Emphysema Assessed by the Goddard Score Predicts Outcomes After Hepatic Resection for Colorectal Liver Metastases
20250 citationsauthor #7
The prognosis-based classification model in resectable pancreatic cancer.
20241 citationsauthor #7
Prognostic Impact of a Decrease in Serum Carbohydrate Antigen 19-9 Levels After Preoperative Therapy for 4 Months or More for Borderline Resectable Pancreatic Cancer Abutting Major Arteries
20240 citationsauthor #9
Impact of Preoperative Osteosarcopenia and Postoperative Administration of Pancrelipase on the Prognosis of Borderline Resectable and Unresectable Locally Advanced Pancreatic Cancer
20242 citationsauthor #2
Prognostic Significance of Sarcopenia and Eicosapentaenoic Acid (EPA) Levels in Patients With Unresectable Pancreatic or Biliary Tract Cancer.
20242 citationsauthor #8
Effect of Chemoradiotherapy on Locoregional Recurrence After Pancreatectomy for Pancreatic Cancer
20242 citationsauthor #3
Changes in Skeletal Muscle Volume During Preoperative Chemotherapy Affect the Outcome of Pancreatic Cancer
20241 citationsauthor #9
Osteosarcopenia is a significant predictor of recurrence and the prognosis after resection for extrahepatic bile duct cancer
202316 citationsauthor #5
Preoperative Therapy for Unresectable Locally Advanced Pancreatic Cancer for ≥6 Months Improves Prognosis After Pancreatectomy
20230 citationsauthor #3
Blood loss in laparoscopic distal pancreatectomy could be underestimated
20233 citationsauthor #7
Multimodal Management for Refractory Biliary Stricture After Living Donor Liver Transplantation.
20232 citationsauthor #10
Liver Only Living Donor Transplantation for Polycystic Disease in a Patient on Chronic Hemodialysis: Case Report.
20230 citationsauthor #10
Impact of C-reactive protein-albumin-lymphocyte (CALLY) index on prognosis after hepatectomy for colorectal liver metastasis.
202338 citationsauthor #7
Zero Mortality in Living-Donor Liver Transplantation for Primary Biliary Cholangitis in Patients With a Meld Score of <20.
20232 citationsauthor #10
A Multidisciplinary Treatment Strategy With Conversion Surgery for Hepatocellular Carcinoma
20235 citationsauthor #5
Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancer
20237 citationsauthor #2
Effect of duration of adjuvant chemotherapy with S-1 (6 versus 12 months) for resected pancreatic cancer: the multicenter clinical randomized phase II postoperative adjuvant chemotherapy S-1 (PACS-1) trial
20235 citationsauthor #14
Open Thoracic Drainage Followed by Proximal Splenic Artery Embolization for Massive Hydrothorax Before Living Donor Liver Transplantation.
20230 citationsauthor #10
Superior mesenteric vein/portal vein contact in preoperative imaging indicates biological malignancy in anatomically resectable pancreatic cancer.
20236 citationsauthor #14
Effects of an enteral nutrient-rich therapy with omega-3 fatty acids in patients with unresectable or recurrent biliary tract cancer or pancreatic cancer during chemotherapy: a case–control study
20225 citationsauthor #2
Conversion surgery for undifferentiated carcinoma with osteoclast-like giant cells of the pancreas: a case report
20227 citationsauthor #4
The effectiveness of adjuvant chemotherapy for Stage I pancreatic cancer based on the UICC 8th edition
20225 citationsauthor #10
Oesophageal elongation using magnets in adult patients.
20220 citationsauthor #8
The impact of C‐reactive protein‐albumin‐lymphocyte (CALLY) index on the prognosis of patients with distal cholangiocarcinoma following pancreaticoduodenectomy
202244 citationsauthor #7
Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer
20226 citationsauthor #1
Effects of Fasting and Administration of Octreotide Acetate and Ulinastatin on Clinical Outcomes of Pancreatic Fistula after Pancreatoduodenectomy
20220 citationsauthor #8
Inhibition of lysosomal acid β-glucosidase and induces cell apoptosis via impairing mitochondrial clearance in pancreatic cancer.
20225 citationsauthor #10
The impact of S-1 for the patient with lymph nodal metastasis biliary tract cancer as adjuvant chemotherapy: a multicenter database analysis
20223 citationsauthor #11
Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer
20215 citationsauthor #1
Inhibition of acid ceramidase elicits mitochondrial dysfunction and oxidative stress in pancreatic cancer cells
202113 citationsauthor #10
How to Perform Curative Laparoscopic Hepatectomy for Intraoperatively Unidentified Hepatocellular Carcinoma
20211 citationsauthor #5
Nafamostat mesilate, a nuclear factor kappa B inhibitor, enhances the antitumor action of radiotherapy on gallbladder cancer cells
20212 citationsauthor #7
Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report
202116 citationsauthor #5
A multicenter clinical randomized phase II study of investigating duration of adjuvant chemotherapy with S-1 (six versus 12 months) for patients with resected pancreatic cancer: PACS-1 study.
20200 citationsauthor #13
Correction to: Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)
20202 citationsauthor #10
Phase II Study of Adjuvant Chemotherapy of Gemcitabine with Nafamostat Mesilate for Pancreatic Cancer
20200 citationsauthor #1
Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)
202043 citationsauthor #10
Claudin 7 as a possible novel molecular target for the treatment of pancreatic cancer.
201911 citationsauthor #6
Prevention of early liver metastasis after pancreatectomy by perioperative administration of a nuclear factor-κB inhibitor in mice.
20192 citationsauthor #2
Intracranial Bleeding during Treatment with Sorafenib for Hepatocellular Carcinoma
20192 citationsauthor #2
Gallbladder cancer accompanied by uncontrollable eosinophilia: report of a case
20195 citationsauthor #3
Frequency and clinicopathological characteristics of biliary tract carcinomas harboring the FGFR2-fusion gene: A prospective observational study (PRELUDE study)
20197 citationsauthor #8
Radical resection of an initially unresectable intrahepatic cholangiocarcinoma after chemotherapy with using gemcitabine, cisplatin, and S-1: report of a case
20193 citationsauthor #4
Correction: Hiroshi Sugano et al. Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells. Cancers 2018, 10, 386
20191 citationsauthor #7
Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo
20183 citationsauthor #3
Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy.
201825 citationsauthor #2
A Case of Remnant Pancreatic Cancer Occurring Eight Yearsafter Pancreatodenectomy
20180 citationsauthor #4
Pomalidomide promotes chemosensitization of pancreatic cancer by inhibition of NF-κB
201812 citationsauthor #3
Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells
201812 citationsauthor #7
Preoperative Platelet to Albumin Ratio Predicts Outcome of Patients with Cholangiocarcinoma.
201835 citationsauthor #7
Recombinant thrombomodulin suppresses tumor growth of pancreatic cancer by blocking thrombin‐induced PAR1 and NF‐&kgr;B activation
201726 citationsauthor #2
Preoperative Platelet-to-Albumin Ratio Predicts Prognosis of Patients with Pancreatic Ductal Adenocarcinoma After Pancreatic Resection.
201768 citationsauthor #8
Glycogen synthase kinase‐3β activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells
20173 citationsauthor #7
Radical resection of a primary unresectable duodenal cancer after chemotherapy using S-1 and cisplatin: report of a case
20176 citationsauthor #5
Abstract 4789: A novel MIF signaling pathway drives the malignant character of pancreatic cancer by targeting NR3C2
20170 citationsauthor #9
Chemotherapy for alpha-fetoprotein producing gastric cancers expressing human epidermal growth factor receptor 2.
20174 citationsauthor #6
Comparison of the outcomes of Hand-sewn vs. Stapler Closure of the pancreatic stump in distal pancreatectomy
20160 citationsauthor #9
Abstract B34: A Novel MIF-driven Signaling Drives Disease Aggressiveness by Targeting NR3C2 in Pancreatic Cancer
20160 citationsauthor #8
Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer.
201619 citationsauthor #7
A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.
2016251 citationsauthor #8
Initial Report of Phase II Study of Adjuvant Chemotherapy of Gemcitabine with Nafamostat Mesilate for Pancreatic Cancer
20161 citationsauthor #1
New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
20168 citationsauthor #2
Pomalidomide Enhanced Antitumor Effect of Gemcitabine and Nab-Paclitaxel for Pancreatic Cancer Cells
20160 citationsauthor #8
Recombinant Thrombomodulin Suppresses Tumor Growth of Pancreatic Cancer by Blocking Thrombin-Induced NF-κB Activation
20161 citationsauthor #3
P-117Phase II study of combination chemotherapy of gemcitabine/S-1 with nafamostat mesilate for advanced unresectable pancreatic cancer. First report
20160 citationsauthor #1
Radical Resection of a Primarily Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy Using Gemcitabine, TS-1, and Nafamostat Mesilate; Report of a Case.
20152 citationsauthor #3
Curative Resection After Gemcitabine, Cisplatin and S-1 Chemotherapy for Initially Unresectable Biliary Duct Cancer: A Case Report.
20156 citationsauthor #2
Effect of NF-κB inhibition on chemoresistance in biliary–pancreatic cancer
201524 citationsauthor #1
Inhibitor of Nuclear Factor ?B Activation Enhances the Antitumor Effect of Radiation Therapy for Pancreatic Cancer
20140 citationsauthor #7
O1-12-1CAN EARLY MEASUREMENT OF URINARY N-ACETYL-β-GLUCOSAMINIDASE HELP PREDICT TOXICITY OF CISPLATIN-BASED CHEMOTHERAPY?
20142 citationsauthor #6
Combination Treatment Using Adenovirus-Mediated CD40 Ligand Gene Delivery and NF-κB Inhibitor for Pancreatic Cancer
20140 citationsauthor #8
Inhibitor of Nuclear Factor κB Activation Enhances the Antitumor Effect of Radiation Therapy for Pancreatic Cancer
20140 citationsauthor #7
Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer
20149 citationsauthor #1
[The current status of home palliative care for patients with advanced cancer at the Jikei University School of Medicine].
20140 citationsauthor #8
Combination Treatment Using Adenovirus-mediated Tumor Necrosis Factor-Alpha Gene Transfer and NF-kappaB Inhibitor for Hepatocellular Carcinoma in Mice
20131 citationsauthor #7
30 cycles of Trans-Arterial Chemoembolisation prolonged survival in a patient with multiple recurrent hepatocellular carcinoma
20130 citationsauthor #2
Erlotinib-induced thrombocytosis in patients with recurrence of pancreatic cancer after distal pancreatectomy.
20133 citationsauthor #1
Anti-Tumor Effect of Synthetic Serine Protease Inhibitor
20130 citationsauthor #2
Inhibition of nuclear factor-κB enhances the antitumor effect of tumor necrosis factor-α gene therapy for hepatocellular carcinoma in mice.
201315 citationsauthor #6
Combination Chemotherapy of Gemcitabine With Nafamostat Mesilate Against Gallbladder Cancer Targeting Nuclear Factor-kappaB Activation
20130 citationsauthor #7
Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for pancreatic cancer in mice.
201319 citationsauthor #6
Nuclear factor κB activity correlates with the progression and prognosis of pancreatic cancer in a mouse model
201310 citationsauthor #2
Phase II Study of Gemcitabine in Combination With Regional Arterial Infusion of Nafamostat Mesilate for Advanced Pancreatic Cancer
201334 citationsauthor #1
Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-κB activation for pancreatic cancer.
201332 citationsauthor #2
Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation.
201321 citationsauthor #6
[A case of stage IV b pancreatic cancer in which a catheter-related infection caused by epidural/subcutaneous reservoir therapy affected palliative home-based care].
20121 citationsauthor #7
Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy.
201210 citationsauthor #2
Inhibition of Nuclear Factor-κB Enhances the Antitumor Effect of Paclitaxel Against Gastric Cancer with Peritoneal Dissemination in Mice
201217 citationsauthor #6
Usage of Eltrombopag for Chronic Immune Thrombocytopenia as a Pretreatment for Splenectomy
20123 citationsauthor #1
Inhibition of NF-kappaB enhances the anti-tumor effect of combination treatment with tumor necrosis factor-alpha (TNF-alpha) gene therapy and gemcitabine for pancreatic cancer in mice
20121 citationsauthor #6
Combination chemotherapy with nafamostat mesilate and oxaliplatin targeting NF-kappa B activation for pancreatic cancer in mice
20120 citationsauthor #2
Hydroxyurea Decreases Gemcitabine Resistance in Pancreatic Carcinoma Cells With Highly Expressed Ribonucleotide Reductase
201218 citationsauthor #4

TIMELINE

2001 29 citations

2004 548 citations

2005 148 citations

2006 21 citations

2007 104 citations

2008 39 citations

2009 135 citations

2010 55 citations

2011 72 citations

2012 50 citations

2013 135 citations

2014 11 citations

2015 32 citations

2016 280 citations

2017 107 citations

2018 87 citations

2019 31 citations

2020 45 citations

2021 37 citations

2022 75 citations

2023 84 citations

2024 8 citations

2025 14 citations

2026 0 citations

T. Uwagawa

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT